Introduction Over the past decade, interest in studying biological markers (biomarkers) for type 2 diabetes (T2D) has increased intensely. This happened because multiple pathobiological processes may contribute to the disease progression, which
Huguette S Brink, Aart Jan van der Lely and Joke van der Linden
). In recent years, adipokines have been posed as the link between adiposity and adverse complications such as insulin resistance. Identification of early biomarkers in pregnant women, who subsequently develop GD, may result in improved understanding of
Ishita Gupta, Allal Ouhtit, Adil Al-Ajmi, Syed Gauhar A Rizvi, Hamad Al-Riyami, Marwa Al-Riyami and Yahya Tamimi
onset and progression of breast malignancy. The present data suggest a putative role of BRIP1 in the onset and progression in breast cancer and the possibility to use this gene as a biomarker. In addition, the small-sample size and lack of patients
Kjell Oberg, Eric Krenning, Anders Sundin, Lisa Bodei, Mark Kidd, Margot Tesselaar, Valentina Ambrosini, Richard P Baum, Matthew Kulke, Marianne Pavel, Jaroslaw Cwikla, Ignat Drozdov, Massimo Falconi, Nicola Fazio, Andrea Frilling, Robert Jensen, Klaus Koopmans, Tiny Korse, Dik Kwekkeboom, Helmut Maecke, Giovanni Paganelli, Ramon Salazar, Stefano Severi, Jonathan Strosberg, Vikas Prasad, Aldo Scarpa, Ashley Grossman, Annemeik Walenkamp, Mauro Cives, Irene Virgolini, Andreas Kjaer and Irvin M Modlin
assessment by imaging, biomarker levels and overall survival represents the fundamental basis for all management strategies. The need to monitor tumor responsiveness, both in clinical trials and in routine practice, is mandatory given the range of expensive
Fabian Eichelmann, Cornelia Weikert, Romina di Giuseppe, Ronald Biemann, Berend Isermann, Matthias B Schulze, Heiner Boeing and Krasimira Aleksandrova
reported associations between chemerin and biomarkers of inflammation, metabolic parameters and anthropometric measures of adiposity ( 13 ). However, little is known about the interrelations of chemerin with inflammation-related adipokines. Particularly
Gudmundur Johannsson, Martin Bidlingmaier, Beverly M K Biller, Margaret Boguszewski, Felipe F Casanueva, Philippe Chanson, Peter E Clayton, Catherine S Choong, David Clemmons, Mehul Dattani, Jan Frystyk, Ken Ho, Andrew R Hoffman, Reiko Horikawa, Anders Juul, John J Kopchick, Xiaoping Luo, Sebastian Neggers, Irene Netchine, Daniel S Olsson, Sally Radovick, Ron Rosenfeld, Richard J Ross, Katharina Schilbach, Paulo Solberg, Christian Strasburger, Peter Trainer, Kevin C J Yuen, Kerstin Wickstrom, Jens O L Jorgensen and on behalf of the Growth Hormone Research Society
Introduction Biological markers (biomarkers) play an essential role in the clinical care of patients, drug development and regulatory approval. Furthermore, biomarkers are linked to surrogate endpoints and clinical endpoints ( 1 , 2 , 3 , 4
Roxanne C S van Adrichem, Aart Jan van der Lely, Martin Huisman, Piet Kramer, Richard A Feelders, Patric J D Delhanty and Wouter W de Herder
patients were reported to be positively correlated with tumor burden ( 29 ), total plasma ghrelin seems not to be a useful biomarker since total plasma ghrelin levels did not discriminate between patients with NETs and healthy controls ( 23 ). Currently
Hathairat Rueangdetnarong, Rattanaporn Sekararithi, Thidarat Jaiwongkam, Sirinart Kumfu, Nipon Chattipakorn, Theera Tongsong and Phudit Jatavan
2 . During early labor, the levels of 8Isop were still significantly higher in the GDM group, whereas the levels of TNFα tended to be increased but did not reach the significant level ( Table 2 ). All the three biomarkers in cord blood were not
Eva O Melin, Jonatan Dereke, Maria Thunander and Magnus Hillman
-up. It would also be of interest to measure the levels of sCD163 in the vitreous of the eye and in the plasma simultaneously. It is important to find biomarkers that can contribute to the understanding of the pathology of DR, that can be used for early
Ram P Narayanan, Bo Fu, Adrian H Heald, Kirk W Siddals, Robert L Oliver, Julie E Hudson, Antony Payton, Simon G Anderson, Anne White, William E R Ollier and J Martin Gibson
Insulin-like growth factors are implicated in the development of diabetic nephropathy. IGF-binding protein 2 (IGFBP2) and IGF2 are expressed in the kidney, but their associations with diabetic nephropathy are unclear. We therefore tested the hypothesis that circulating levels of IGF2 and IGFBP2 predict longitudinal renal function in individuals with type 2 diabetes.
Design and methods
IGFBP2 and IGF2 measurements were performed in 436 individuals (263 males) with type 2 diabetes. Linear mixed-effect regression analysis was used to model the relationship between plasma IGFBP2 concentration and longitudinal changes in estimated glomerular filtration rate (eGFR) over an 8-year period. Analyses were also performed for IGF1, IGF2, IGFBP1 and IGFBP3 concentrations as predictors of longitudinal renal outcomes.
High IGFBP2 concentration at baseline was associated with a decreased eGFR over an 8-year period (β=−0.02, (95% confidence interval −0.03 to −0.01), P<0.001). High IGFBP1, IGFBP2 and IGFBP3 were also associated with low baseline eGFR concentration.
This study demonstrates that IGFBP2 is a predictor of longitudinal deterioration of renal function in type 2 diabetes.